ERBB2 and breast carcinoma: In a study investigating the antitumor activity of AZD8931 in preclinical models of EGFR-overexpressed and HER2 non-amplified breast cancer cell lines (SUM 149 and FC-IBC-02, respectively), significant suppression of cell growth and induced apoptosis was observed in combination with paclitaxel therapy [51].